Physician profile
Amber Moss
NPI 1386022630
$982.11
in general payments reported to CMS, 2019-2025
15 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.05 · 2020: $72.69 · 2023: $126 · 2024: $568 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $338.50 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $159.89 | 2023-2025 | |
| Glaxosmithkline, LLC. | $80.96 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Emd Serono, INC. | $72.69 | 2020 | |
| Lilly USA, LLC | $67.00 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $58.24 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $40.57 | 2019-2024 | Tepezza |
| Medtronic, INC. | $37.96 | 2024-2025 | Intellis Adaptivestim |
| Ardelyx, INC. | $37.02 | 2024-2025 | Ibsrela |
| Philips North America LLC | $19.89 | 2024 | (Ck7) Extended Holter |
| Alexion Pharmaceuticals, INC. | $18.23 | 2024 | Strensiq |
| Pfizer INC. | $17.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.33 | 2024 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $14.96 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $3.87 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.